Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

Efficacy and safety of infliximab in psoriasis patients previously treated with etanercept: Interim results

An open-label trial enrolled 210 patients with plaque psoriasis to treatment with infliximab after they had failed to respond to etanercept with or without methotrexate or ciclosporin. Infliximab (5 mg/kg) was administered at weeks 0, 2 and 6, 2 weeks after the last dose of etanercept. A safety assessment was conducted at week 10. Results are presented for the first 105 patients. The primary endpoint was the percentage of patients who received at least one dose of infliximab and had a Physicians Global Assessment (PGA) score of 1 or less at week 10. Over half (64.4%) of patients had a response at week 10. The majority of patients had a ...